Ji Chengjian, Cong Rong, Wang Yi, Wang Yamin, Zhang Qijie, Zhou Xiang, Xing Qianwei, Song Ninghong
Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China.
Department of Urology, Affiliated Hospital of Nantong University, Nantong, 226001, China.
Ann Transl Med. 2019 Dec;7(23):785. doi: 10.21037/atm.2019.11.32.
Nicotinamide phosphoribosyltransferase (NAMPT), also known as pre-B-cell colony-enhancing factor (PBEF) or visfatin, has been reported to be a crucial factor involved in tumor metabolism, angiogenesis and cell apoptosis. However, its definite roles in patients with malignant cancer remain unclear.
Three online databases PubMed, Embase and Web of Science were looked through comprehensively for eligible articles, published before November, 2018. Pooled hazard ratios (HRs) with 95% confidence intervals (CIs) of overall survival (OS) or disease-free survival time or recurrence-free survival (DFS/RFS) were calculated to determine the associations between NAMPT expression and cancer prognosis.
A total of ten eligible studies were finally enrolled for this analysis. Our results indicated that elevated NAMPT expression was associated with poor OS in breast cancer by both univariate and multivariate analysis (pooled HR =3.23, 95% CI: 1.93-5.41, I=21.1%, P=0.283; pooled HR =3.34, 95% CI: 2.13-5.22, I=0.0%, P=0.791; respectively) and in gastric cancer by univariate analysis (pooled HR =2.47, 95% CI: 1.07-5.73, I=91.1%, P=0.001). Moreover, high expression of NAMPT was also related to poor DFS/RFS in breast cancer by univariate and multivariate analysis (pooled HR =3.85, 95% CI: 2.59-5.71, I=0.0%, P=0.700; pooled HR =3.43, 95% CI: 2.36-4.99, I=0.0%, P=0.737; separately). Similar results could be found in urothelial carcinoma (pooled HR =3.14, 95% CI: 1.73-5.71, I=47.8%, P=0.166; pooled HR =3.06, 95% CI: 1.57-5.98, I=0.0%, P=0.860). Besides, the translational level of NAMPT was also validated by UALCAN and the Human Protein Atlas database [immunohistochemistry (IHC)].
Our results shed light on that NAMPT might be an oncogenic factor in breast cancer, gastric cancer and urothelial carcinoma.
烟酰胺磷酸核糖转移酶（NAMPT），也被称为前B细胞集落增强因子（PBEF）或内脂素，据报道是参与肿瘤代谢、血管生成和细胞凋亡的关键因素。然而，其在恶性肿瘤患者中的具体作用仍不清楚。
全面检索了三个在线数据库PubMed、Embase和Web of Science，查找2018年11月之前发表的符合条件的文章。计算总生存（OS）或无病生存时间或无复发生存（DFS/RFS）的合并风险比（HRs）及95%置信区间（CIs），以确定NAMPT表达与癌症预后之间的关联。
最终纳入10项符合条件的研究进行该分析。我们的结果表明，在乳腺癌中，单因素和多因素分析均显示NAMPT表达升高与较差的OS相关（合并HR =3.23，95% CI：1.93 - 5.41，I =21.1%，P =0.283；合并HR =3.34，95% CI：2.13 - 5.22，I =0.0%，P =0.791；分别），在胃癌中，单因素分析显示NAMPT表达升高与较差的OS相关（合并HR =2.47，95% CI：1.07 - 5.73，I =91.1%，P =0.001）。此外，在乳腺癌中，单因素和多因素分析均显示NAMPT高表达也与较差的DFS/RFS相关（合并HR =3.85，95% CI：2.59 - 5.71，I =0.0%，P =0.700；合并HR =3.43，95% CI：2.36 - 4.99，I =0.0%，P =0.737；分别）。在尿路上皮癌中也发现了类似结果（合并HR =3.14，95% CI：1.73 - 5.71，I =47.8%，P =0.166；合并HR =3.06，95% CI：1.57 - 5.98，I =0.0%，P =0.860）。此外，NAMPT的翻译水平也通过UALCAN和人类蛋白质图谱数据库[免疫组织化学（IHC）]得到验证。
我们的结果表明，NAMPT可能是乳腺癌、胃癌和尿路上皮癌中的致癌因子。
